

RESEARCH ARTICLE

Open Access

# Complex II subunit SDHD is critical for cell growth and metabolism, which can be partially restored with a synthetic ubiquinone analog



Aloka B. Bandara<sup>1,2\*</sup>, Joshua C. Drake<sup>1</sup> and David A. Brown<sup>3</sup>

## Abstract

**Background:** Succinate dehydrogenase (Complex II) plays a dual role in respiration by catalyzing the oxidation of succinate to fumarate in the mitochondrial Krebs cycle and transferring electrons from succinate to ubiquinone in the mitochondrial electron transport chain (ETC). Mutations in Complex II are associated with a number of pathologies. SDHD, one of the four subunits of Complex II, serves by anchoring the complex to the inner-membrane and transferring electrons from the complex to ubiquinone. Thus, modeling SDHD dysfunction could be a valuable tool for understanding its importance in metabolism and developing novel therapeutics, however no suitable models exist.

**Results:** Via CRISPR/Cas9, we mutated SDHD in HEK293 cells and investigated the in vitro role of SDHD in metabolism. Compared to the parent HEK293, the knockout mutant HEK293 $\Delta$ SDHD produced significantly less number of cells in culture. The mutant cells predictably had suppressed Complex II-mediated mitochondrial respiration, but also Complex I-mediated respiration. SDHD mutation also adversely affected glycolytic capacity and ATP synthesis. Mutant cells were more apoptotic and susceptible to necrosis. Treatment with the mitochondrial therapeutic idebenone partially improved oxygen consumption and growth of mutant cells.

**Conclusions:** Overall, our results suggest that SDHD is vital for growth and metabolism of mammalian cells, and that respiratory and growth defects can be partially restored with treatment of a ubiquinone analog. This is the first report to use CRISPR/Cas9 approach to construct a knockout SDHD cell line and evaluate the efficacy of an established mitochondrial therapeutic candidate to improve bioenergetic capacity.

**Keywords:** Electron transport chain, Complex II, Krebs cycle, Succinate dehydrogenase, SDHD, CRISPR/Cas9, Respiration, Oxygen consumption, Glycolysis, ATP synthesis, Apoptosis, Necrosis, ROS, Idebenone

\* Correspondence: [abandara@vt.edu](mailto:abandara@vt.edu)

<sup>1</sup>Department of Human Nutrition, Foods and Exercise, Virginia Tech, Blacksburg, VA 24061-0913, USA

<sup>2</sup>Department of Biomedical Sciences and Pathobiology, Virginia Tech, Blacksburg, VA 24061-0342, USA

Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

## Background

Mitochondria generate the majority of adenosine triphosphate (ATP) through the electron transport chain (ETC). Succinate dehydrogenase (Complex II; EC 1.3.5.1) uniquely serves as a component of both the Krebs cycle and the ETC [1, 2]. As a component of the Krebs Cycle, Complex II catalyzes oxidation of succinate to fumarate [1, 3], whereas in the ETC, it is one of two entry points for electrons, acquiring electrons from succinate and donating them to ubiquinone (CoQ) [1–3]. Thus, impairments in Complex II function can have severe consequences for maintaining energetic homeostasis. Mutations in Complex II subunits have been found in patients with mitochondrial respiratory deficiency [4], as well as a number of cancers [5–7]. Therefore, an in-depth understanding of Complex II in energetic homeostasis and its viability as a target for treatment is warranted.

Complex II carries four protein subunits [2], all of which are encoded by nuclear genes. Two subunits, SDHA and SDHB, are localized on the matrix side of the inner membrane, and carry the binding site for succinate, three FeS clusters, as well as a flavoprotein bound to an FAD cofactor [8]. The two remaining subunits, SDHC and SDHD, are hydrophobic and anchor the complex to the inner-membrane. Subunits SDHC and SDHD form the CoQ binding site of Complex II and serve as terminal electron transfers from Complex II to CoQ. In particular, mutation of SDHD has been noted in patients with paragangliomas and pheochromocytomas [7]. Expression of truncated SDHD cDNA in Chinese hamster fibroblasts led to increased steady-state levels of superoxide generation, supporting the hypothesis that mutations in SDHD may contribute to carcinogenesis [9]. Therefore, given the particular role of SDHD in anchoring Complex II to the inner-membrane, passaging electrons to CoQ, and noted pathologies, modeling SDHD dysfunction could be a valuable tool for understanding the role of Complex II in metabolism and developing novel therapeutics. To date, however, suitable models for molecular examinations of any Complex II subunit do not exist.

We successfully used a CRISPR/cas9 approach to mutate the SDHD subunit of Complex II in HEK293 cells, and characterized its requirement for mitochondrial respiration, ATP synthesis, and cell growth in vitro. Furthermore, we demonstrate the efficacy of the mitochondrial therapeutic idebenone to improve mitochondrial dysfunction in cells with SDHD mutation. Our results demonstrate the necessity of SDHD for energetic homeostasis and suggests it as a viable target for therapies aimed to improve mitochondrial function.

## Results

### Construction of mutant HEK293 $\Delta$ SDHD

The single guide RNA (sgRNA) sequences were designed based on the 609 bp long *SDHD* nucleotide sequence of


*Homo sapiens* (GenBank locus ID KR710199.1) using Integrated DNA Technologies' online tool (Skokie, IL; [https://www.idtdna.com/site/order/designtool/index/CRISPR\\_CUSTOM](https://www.idtdna.com/site/order/designtool/index/CRISPR_CUSTOM)). A 118-bp site of the forward strand of *SDHD* was predicted as the most reliable for mutation with an on-target specificity score of 68% and off-target score of 58%. The guide strand predicted was TCTGTT GCTTCGAACTCCAG, which is located right upstream of the protospacer adjacent motif (PAM) sequence TGG (Fig. 1a). The constructed mutant HEK293 $\Delta$ SDHD was validated by Western immunoblotting. The predicted molecular weight of SDHD is approximately 17 kDa. Nevertheless, the antibody used for mutant validation was anticipated to produce an additional band of about 29 kDa as well on the blot from parent cells (see the details from the vendor: <https://www.lsbio.com/antibodies/cbt1-antibody-sdhd-antibody-n-terminus-wb-western-ls-c345301/356234>). Our mutant HEK293 $\Delta$ SDHD was found missing both 17 kDa and 29 kDa protein bands (Fig. 1b).

We then PCR amplified and sequenced the *SDHD* region encompassing the CRISPR targeting site (at 118-bp) of the mutant. The results indicated that an INDEL mutation has been generated at a site two bases upstream of the GTT PAM sequence. Two bases (a C and an A) have been

deleted from this site and one base (a G) has been inserted at the deletion site (new Fig. 1c). As a result, the whole amino acid sequence downstream of this INDEL site has been altered. Moreover, a stop codon has been inserted 180 bases downstream of the GTT PAM sequence.

Using the online CRISPR prediction site of the Integrated DNA Technologies, we identified the top three potential off-target sites (Table 1). The DNA regions encompassing these sites were PCR amplified and sequenced. The DNA sequences of these sites of the mutant were identical to those of the parent cell line indicating absence of any off-target genetic alterations in the genome of the mutant.

We then investigated whether mutation in *SDHD* altered the expression of other subunits of the five ETC complexes. Expression of complex II subunit SDHB (Fig. 1d and f) decreased significantly in the mutant ( $p < 0.0001$ ) suggesting that SDHD expression has direct impact on expression of other subunits of the complex II. Moreover, expression of complex I subunit NDUFB8 (Fig. 1d and e), complex IV subunit MT-CO1 (Fig. 1d and h), and complex V subunit ATP5A (Fig. 1d and i) decreased significantly in the mutant ( $p = 0.0249, 0.0034, \text{ and } 0.0073$ , respectively) suggesting an association in protein expression between complexes II and other ETC complexes. Nevertheless, the expression of complex III subunit UQCRC2 (Fig. 1d and g) was not different



between the parent and the mutant suggesting that mutation did not impact expression of this subunit/complex.

#### Loss of SDHD increases apoptosis and necrosis

Compared to the parent HEK293, the mutant HEK293ΔSDHD produced significantly increased amount of ROS at 0 h (immediately after addition of the substrate to the reaction;  $p = 0.0128$ ; Fig. 2a). Nevertheless, the mutant produced significantly decreased ROS

amounts at 24 h ( $p = 0.0035$ ) and 72 h ( $p < 0.0001$ ) after addition of the substrate. These observations suggest that disruption of SDHD results in subsequent decrease of ROS generation over time. It is possible that leakage of electrons due to impaired complex II caused increased ROS production at early stages of cell growth (i.e., 0 h). Nevertheless, the severe impairment of electron transport may have caused decreased overall electron leak and subsequent ROS generation at late stages of growth (i.e., 24 and 48 h). At all the time points, the


**Table 1** Targeted mutagenesis site, possible off-target sites, the respective protospacer adjacent motif (PAM) sequences, and forward (F) and reverse (R) oligonucleotide primers used for PCR amplification and DNA sequencing


Guide strand	PAM	Chromosome in human genome	Oligo primers used in sequencing (5'-3')
<u>Targeted mutagenesis site</u>			
TCTGTTGCTTCGAACTCCAG	TGG	11	GTTCTGTGCAACAAATTGAT (F) GTCAGTAACAACCTTGCCAA (R)
<u>Possible off-target sites</u>			
TATG-TGCTTCGAGCTCCAG	AGG	19	CTTCTGTGCCTTACGTACCA (F) TGTACTGTAACCAAGTACGC (R)
TCTCTTGCTTC-AACTCCAG	AGG	3	GTAGAGGCAAGGTCTTCTCTG (F) TTACCAGCCTCCTGGACCT (R)
TCAGCTTGCTTCGAACTCCTG	GAG	12	TTAGCAATAACTAGTCCAAC (F) CAGAGGTCCTGTAGTGTGG (R)

mutant displayed significantly increased apoptosis ( $p < 0.0001$ ,  $< 0.0001$ ,  $< 0.0001$ , and  $= 0.0043$  respectively at 0, 2, 24, and 72 h post-incubation; Fig. 2b). The mutant also showed significantly increased necrosis ( $p < 0.0001$  for each time point; Fig. 2c). Our findings indicate that disruption of *SDHD* made the cells more apoptotic and susceptible to necrosis.

### Loss of *SDHD* impairs growth

After 4 days of incubation in growth media, the number of cells recovered from the mutant HEK293 $\Delta$ *SDHD* culture was  $\sim 73\%$  less than the amount recovered from parent HEK293 culture ( $p = 0.0002$ ; Fig. 3a). The doubling of mutant over 4 days was significantly slower compared to that of the parent during the same duration of





growth ( $p = 0.0008$ ; Fig. 3b), suggesting that SDHD is vital for cell growth.

#### Loss of SDHD impairs mitochondrial respiration

Oxygen consumption was measured using Oroboros Oxygraph 2k. Mutation in SDHD decreased oxygen consumption all along the ETC (Fig. 4a and f). Complex I respiration was significantly decreased in mutant cells compared to parent ( $p = 0.0019$ ). Subsequent to rotenone treatment, oxygen consumption of both parent and mutant decreased, but the oxygen consumption of mutant cells was significantly less than that of parent cells ( $p = 0.0101$ ). In response to treatment with succinate, Complex II-mediated oxygen consumption was significantly repressed in mutant cells compared to parent cells ( $p = 0.0002$ ), further confirming the effect SDHD mutation. The mutant also had decreased OXPHOS.

capacity ( $p = 0.0002$ ) and maximal respiration ( $p = 0.0017$ ). Oxygen consumption of permeabilized cells was also assessed using an Agilent Seahorse XFe96 Analyzer (Fig. 4b). In the mutant, basal respiration ( $p < 0.0001$ ; Fig. 4c), reserve respiratory capacity ( $p < 0.0001$ ; Fig. 4d), and maximal respiratory capacity ( $p < 0.0001$ ; Fig. 4e) decreased significantly. Oroboros O2k and Seahorse OCR assays collectively indicate a severe impairment of cellular respiration due to SDHD disruption.


#### Loss of SDHD impairs glycolytic capacity and ATP synthesis of cell lines

Extracellular Acidification Rate (ECAR) of intact cells was determined using an Agilent Seahorse XFe96 Analyzer (Fig. 5a). Both glycolysis ( $p < 0.0001$ ; Fig. 5b) and glycolytic capacity ( $p < 0.0001$ ; Fig. 5c) decreased significantly in mutant cells. The findings indicate an association between SDHD function and glycolysis. The


mutant cells produced significantly less ATP than parent cells at two different cell densities ( $p < 0.0001$  when 3500 or 10,000 cells/well were used; Fig. 5d). Impaired ATP synthesis was consistent with suppressed mitochondrial and glycolytic metabolism.

#### Improved respiration and growth of HEK293 $\Delta$ SDHD mutant cells treated with mitochondrial therapeutic idebenone

Idebenone is a short-chain benzoquinone with greater hydrophilicity [10], which has shown promise as a therapeutic for mitochondrial dysfunction [10–12]. We tested whether idebenone modified oxygen consumption of mutant HEK293 $\Delta$ SDHD cells by Seahorse XFe96 and O2k respirometry. In Seahorse assay, treatment of permeabilized mutant cells with 1  $\mu$ M idebenone significantly increased basal respiration ( $p < 0.0001$ ; Fig. 4c) and maximal respiratory capacity ( $p < 0.0001$ ; Fig. 4e), but not reserved respiratory capacity ( $p = 0.8847$ ; Fig. 4d). In O2k respirometry assay, in the presence of succinate, idebenone was incrementally added 10 min apart, with concentrations of 1  $\mu$ M, following by three subsequent injections of 5  $\mu$ M each (Fig. 6a). Compared to vehicle (DMSO), 1  $\mu$ M idebenone elicited a non-statistically significant increase in oxygen consumption ( $p = 0.1250$ ; Fig. 6a). Subsequent dose of 5  $\mu$ M idebenone significantly increased oxygen consumption compared to vehicle in mutant cells ( $p = 0.0119$ ), which peaked after the second dose of 5  $\mu$ M idebenone ( $p = 0.0508$ ; Fig. 6a). After the final injection of 5  $\mu$ M idebenone, OXPHOS capacity was measured by adding ADP. Idebenone treated mutant cells had significantly improved OXPHOS capacity compared to the DMSO treated cells ( $p = 0.0148$ ) (Fig. 6a).



**Fig. 4** Respiration, of cell lines. Oxygen consumption rates measured using Oroboros O2k per million cells in response to treatment with glutamate-malate (G/M), rotenone, succinate, ADP, and FCCP (A) are shown. The mean oxygen consumption rates were compared between the parent HEK293 and the mutant HEK293ΔSDHD. The p values for the differences between the mean values were 0.0019, 0.0101, 0.0002, 0.0002 and 0.0017, respectively for Complex I respiration, rotenone treatment, Complex II respiration, OXPHOS capacity, and maximal respiration. Oxygen consumption rate (OCR) was measured using Agilent Seahorse XFe96 of parent cells treated DMSO (Parent + DMSO), mutant cells treated DMSO (Mutant + DMSO), and mutant cells treated 1μM idebenone (Mutant + Ideb). OCR per 20,000 permeabilized cells (B), and the calculated basal respiration (C), reserve respiratory capacity (D) and maximal respiratory capacity (E) are shown. The mean OCR values were compared between the parent versus the mutant or DMSO treatment versus idebenone treatment. Error bars represent the SE of the mean. Representative Oroboros oxygraphs depicting oxygen consumption of cell lines (F) are shown. The top and bottom panels represent parent and mutant cell lines, respectively. The oxygen consumption rate is illustrated by the red line




We next investigated whether long-term idebenone treatment would influence cell growth. Due to the slow growth of HEK293 $\Delta$ SDHD cells (Fig. 6b), cells were grown for 10 days in growth media where either 1, 5, or 10  $\mu$ M idebenone was added to the media. After 10 days, 25.4% more cells were recovered from cells treated with 1  $\mu$ M idebenone compared to the DMSO control ( $p = 0.00959$ ; Fig. 6b). However, treatment with 5  $\mu$ M idebenone did not improve growth of the mutant ( $p = 0.9433$ ; Fig. 6b), whereas treatment with 10  $\mu$ M idebenone caused cell death (not shown).

## Discussion

Herein, we successfully used a CRISPR/Cas9 approach to mutate *SDHD*, a Complex II subunit in the inner-membrane region [1, 2], in HEK293 cells, generating the first such model to study the role of this essential Complex II subunit. The INDEL recombination events at the 118-bp site disrupted or altered the whole amino acid sequence downstream of the PAM site. And, mutagenesis procedure did not create any detectable off-target

genetic alterations. In agreement with the observed alteration of the *SDHD* DNA sequence, amino acid level expression of the protein SDHD was totally disrupted in the mutant. Moreover, as a result of the *SDHD* mutation, expression of another complex II subunit (*SDHB*) decreased significantly suggesting interdependency in expression among different subunits of this complex. Quite interestingly, the expression of a complex I subunit (*NDUFB8*), a complex IV subunit (*MT-CO1*), and a complex V subunit (*ATP5A*) also decreased significantly in the mutant suggesting an association in protein expression between complex II and other complexes. Nevertheless, the *SDHD* mutation did not alter expression of the complex III subunit *UQCRC2* suggesting independency of this complex from complex II in terms of protein expression.

Due to the role of Complex II in the ETC and Krebs cycle [1–3] as well as the association of *SDHD* mutations with disease pathologies [7], understanding the contribution of *SDHD* to cellular metabolism is warranted. Mutation in *SDHD* disrupted respiration all



along the ETC, suppressed glycolysis and overall ATP synthesis, as well as limited cellular growth. Importantly, acute treatment with the synthetic ubiquinone analog idebenone was sufficient to improve Complex II-mediated mitochondrial respiration, OXPHOS capacity, and cell proliferation.

Predictably, mutation of SDHD inhibited Complex II-mediated respiration. Interestingly, however, mutation in SDHD significantly reduced Complex I-mediated respiration as well. Since Complex II drives Krebs cycle in a clock-wise direction by converting succinate to fumarate, we hypothesize that mutation of SDHD slowed and/or disrupted Krebs cycle production of NADH, the substrate for Complex I. Mutation in SDHD also impaired OXPHOS capacity, maximal respiration, and ATP synthesis. Taken together, impairment in the SDHD subunit of Complex II is sufficient to impair overall ETC energy production.

Glycolysis, as determined by ECAR, was significantly reduced in HEK293ΔSDHD compared to parent cells. Reduced glycolysis may reflect a lower demand for pyruvate due to disrupted Krebs cycle as a result of mutation in SDHD, representing a potential negative feedback on glycolysis. Also, inhibition of mitochondrial respiration with oligomycin did not elicit a change in glycolysis in mutant cells, further reflecting impaired mitochondrial respiration. In addition to the suppressed metabolism, we also noted significantly slower growth in mutant cells compared to parent cells in culture media, which is likely reflective of the metabolic impairment in mutant cells.

Mutation of SDHD increased apoptosis and necrosis. The impaired glycolysis and mitochondrial respiration may have weakened the cell and cell membrane of the mutant making the cells more apoptotic and susceptible to necrosis. Quite interestingly, the long-term ROS generation declined as a result of SDHD mutation. In general, electrons that do not follow the normal order of the ETC pathway and instead leaked out are eventually transferred directly to O<sub>2</sub> to generate ROS [13, 14]. In our SDHD mutant, it is possible that impairment of clock-wise direction of Krebs cycle may have decreased the synthesis of NADH and FADH<sub>2</sub>, the two electron donors to the ETC. Thus, limited donation of electrons may have led decreased electron transport through the ETC as well as decreased electron leakage out of the ETC giving rise to decreased ROS generation.

Finally, we explored whether SDHD mutation could be bypassed to improve some of the phenotypes observed. Idebenone, is a short-chain benzoquinone that is more hydrophilic than ubiquinone [10], and has potential as a therapeutic for conditions associated with oxidative stress and mitochondrial dysfunction [10–12, 15–22]. Treatment with varying concentrations of idebenone improved Complex II-mediated oxygen consumption and OXPHOS capacity, suggesting that the ubiquinone analog idebenone is able to substitute for Complex II as an electron donor to improve ETC function. Interestingly, long-term treatment with 1 μM of idebenone increased cell proliferation in HEK293ΔSDHD cells whereas 5 μM did not. Idebenone is known to have cell-type specific

effects on cell proliferation [23–25]. While an increase in cell proliferation in our mutant HEK293 $\Delta$ SDHD cells with idebenone is likely a result of improved substrate utilization, cell type should be taken into consideration for mitochondrial targeted therapies as to how other process may be influenced.

## Conclusions

We generated a novel mutant of the Complex II subunit SDHD via CRISPR/Cas9 that resulted in severe augmentation to mitochondrial respiration and cell metabolism as well as suppressed growth. This novel tool could be valuable for testing potential mitochondrial-focused therapeutics as well as elucidating other mechanisms regulated by Complex II function.

## Methods

### Cell lines and culture conditions

Human embryonic kidney cell line 293 (HEK293) was kindly provided by Dr. Joseph Ruiz at Enzerna Biosciences (Raleigh, NC). Media and reagents for growing and maintaining cells were purchased from Life Technologies Corporation (Carlsbad, CA). The cells were maintained in Dulbecco's Modified Eagle's medium (DMEM) supplemented with 10% (by volume) fetal bovine serum and 1% penicillin-streptomycin. Cells were sustained in a humidified incubator at 37 °C and 5% CO<sub>2</sub>. A 0.25% trypsin-EDTA solution was used for detachment of cells. One Shot Stbl3 Chemically Competent cells of *Escherichia coli* (Life Technologies Corporation) were used for constructing the mutagenesis plasmid. Bacteria carrying the plasmids were maintained in Luria Bertani (Sigma-Aldrich, St. Louis, MO) agar or broth, and sustained in a humidified incubator at 37 °C.

### Construction and validation of SDHD mutant

Top and bottom sgRNA sequences for SDHD site were designed and purchased from Integrated DNA Technologies (Skokie, IL). sgRNA oligonucleotides were cloned into plasmid px458 (Addgene, Watertown, MA) and HEK293 cells were transfected with recombinant px458 plasmid using transfection reagent Xfect (Takara Bio USA Inc., Mountain View, CA). Clones with mutation in SDHD were picked using procedures described elsewhere [26]. Disruption of SDHD synthesis was validated by Western Immuno-blotting using rabbit polyclonal antibody SDHD (1:1000 in blocking buffer) (Cat# LS-C345301–100; Life-Span Biosciences Inc., Seattle, WA) and rabbit polyclonal antibodies to  $\beta$ -Actin (1:10,000) (Cat# ab8227, Abcam Inc., Cambridge, MA). A clone missing the protein bands representing SDHD was chosen for further work and designated as HEK293 $\Delta$ SDHD (Fig. 1).

The SDHD DNA region including the targeted mutation site was PCR amplified using the primers shown in

Table 1 and sequenced by Sanger Sequencing using the same primers. Moreover, the DNA regions encompassing the top three off-targets were PCR amplified and sequenced using the primers shown in Table 1.

Expression of protein subunits representative to each of the five ETC complexes was examined by Western immunoblotting using Total OXPHOS Human WB Antibody Cocktail (Cat# ab110411, Abcam). Since the expression of complexes I and IV subunits was not clearly visible in Western blots with this antibody, the expression of these two complexes was examined separately by Western immunoblotting using antibodies to NDUFB8 (complex I; Cat# ab192878, Abcam) and MT-CO1 (complex IV; Cat# ab203912, Abcam).

### Cell growth and metabolism

Aliquots of 100,000 cells of the parent HEK293 and the mutant HEK293 $\Delta$ SDHD were introduced into 75 cm<sup>2</sup> flasks each carrying 25 ml growth media. After 4 days of incubation, cell numbers were quantified in triplicates. Generation of reactive oxygen species (ROS) was measured using ROS-Glo H<sub>2</sub>O<sub>2</sub> Assay (Cat# G8820; Promega Corporation, Madison, WI). Apoptosis and necrosis were assessed using RealTime-Glo Annexin V Apoptosis and Necrosis Assay (Cat# JA1011; Promega). Extracellular Acidification Rate (ECAR) was determined with an Agilent Seahorse XFe96 analyzer [27, 28], and glycolysis and glycolytic capacity were calculated as described elsewhere [28]. Oxygen Consumption Rate (OCR) of saponin-permeabilized cells was assayed with an Agilent Seahorse XFe96 analyzer, and basal respiration, reserve respiratory capacity and maximal respiratory capacity were calculated as described elsewhere [28]. Oxygen consumption of saponin-permeabilized cells [29] was also measured by Oroboros O2k respirometry [30, 31]. Cellular ATP pool was measured using Mitochondrial ToxGlo Assay (Promega Corporation, Madison, WI).

### Restoring the impaired growth and respiration of the mutant

Effectiveness of the potential mitochondrial therapeutic idebenone in restoring the growth defects of the mutant HEK293 $\Delta$ SDHD was evaluated. In this procedure, mutant cells were cultured on 6-well plates at 2000 cells/well in DMEM medium supplemented 1, 5, or 10  $\mu$ M of idebenone. Fresh media containing the drug was added on days 3, 6 and 9, and the cell counts in wells of triplicates was determined following 10 days incubation. Efficacy of idebenone in improving respiration of permeabilized mutant cells was measured by O2k respirometry as described above with the following modification: subsequent to succinate injection, idebenone was injected into chambers at 1 or 5  $\mu$ M final concentration.

The control groups received DMSO. Moreover, effectiveness of idebenone in improving OCR of permeabilized cells was assessed with the Agilent Seahorse XFe96 analyzer as outlined above with the following modification: cells grown overnight in XFe96 culture plates were washed, and glucose-free DMEM (pH 7.4) supplemented with 10 mM glucose, 10 mM sodium pyruvate, 2 mM glutamine, 20 µg/ml saponin and 1 µM of idebenone was added to the wells prior to incubating for 40 min at 37 °C in a CO<sub>2</sub>-free station. The control wells received the same medium added with DMSO but without idebenone.

### Statistical analyses

Student's t-tests were performed using Microsoft Excel program (Microsoft, Redmond, WA) or GraphPad Prism 7 (GraphPad Software, San Diego, CA) to compare the means of the parent versus mutant or vehicle control versus idebenone treatment. The ECAR data were analyzed by repeated measures ANOVA using GraphPad Prism 8. Mean differences between groups were considered statistically significant at  $p < 0.05$ .

### Abbreviations

ETC: Electron transport chain; SDHD: Succinate dehydrogenase subunit D; OXPHOS: Oxidative phosphorylation; ATP: Adenosine triphosphate; CRISPR-Cas9: Clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9; DMSO: dimethyl sulfoxide; ROS: Reactive oxygen species; OCR: Oxygen consumption rate

### Acknowledgements

The authors would like to thank Dr. Joseph Ruiz of Enzerna Biosciences for the mammalian cell line HEK293, Nicholas Catanzaro of the Virginia Maryland College of Veterinary Medicine (VMCVM) for the valuable support with western immuno-blotting, Harini Sooryanarain of VMCVM for the support with the fluorescence and luminescence assays, Alex Thomson and Michael Allen of the Department of Human Nutrition, Foods & Exercise (HNFE) for the support with Seahorse assay, and Justin Perry and Grace Davis of HNFE for the support with Oroboros O2k.

### Authors' contributions

A.B.B. and D.A.B. conceived and planned the study. A.B.B. constructed the mutant and ran the assays. A.B.B. and J.C.D. analyzed the data, interpreted the results, and wrote the manuscript. All authors have read and approved the manuscript.

### Funding

This study was funded by Start-up Funds from Virginia Tech to D.A.B. (VT Fund #235170) and Start-up Funds from Virginia Tech (VT fund #178736) and NIH (R00 AG057825-03) to J.C.D. The funding bodies played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

### Availability of data and materials

All data generated or analyzed during this study are included in this published article. Any additional data generated during the current study are available from the corresponding author on reasonable request.

### Declarations

### Ethics approval and consent to participate

Not applicable.

### Consent for publication

Not applicable.

### Competing interests

Authors declare no competing interests.

### Author details

<sup>1</sup>Department of Human Nutrition, Foods and Exercise, Virginia Tech, Blacksburg, VA 24061-0913, USA. <sup>2</sup>Department of Biomedical Sciences and Pathobiology, Virginia Tech, Blacksburg, VA 24061-0342, USA. <sup>3</sup>Mitochondrial Solutions, LLC, 800 Draper Road, Blacksburg, VA 24060, USA.

Received: 4 November 2020 Accepted: 9 May 2021

Published online: 12 June 2021

### References

- Cecchini G. Function and structure of complex II of the respiratory chain. *Annu Rev Biochem.* 2003;72(1):77–109. <https://doi.org/10.1146/annurev.biochem.72.121801.161700>.
- Sun F, Huo X, Zhai Y, Wang A, Xu J, Su D, et al. Crystal structure of mitochondrial respiratory membrane protein complex II. *Cell.* 2005;121(7):1043–57. <https://doi.org/10.1016/j.cell.2005.05.025>.
- Miyadera H, Shiomi K, Ui H, Yamaguchi Y, Masuma R, Tomoda H, et al. Atpenins, potent and specific inhibitors of mitochondrial complex II (succinate-ubiquinone oxidoreductase). *Proc Natl Acad Sci U S A.* 2003;100(2):473–7. <https://doi.org/10.1073/pnas.0237315100>.
- Bourgeron T, Rustin P, Chretien D, Birch-Machin M, Bourgeois M, Viegas-Pequignot E, et al. Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency. *Nat Genet.* 1995;11(2):144–9. <https://doi.org/10.1038/ng1095-144>.
- Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. *Am J Hum Genet.* 2001;69(1):49–54. <https://doi.org/10.1086/321282>.
- Niemann S, Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. *Nat Genet.* 2000;26(3):268–70. <https://doi.org/10.1038/81551>.
- Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. *Science.* 2000;287(5454):848–51. <https://doi.org/10.1126/science.287.5454.848>.
- Bezawork-Geleta A, Rohlena J, Dong L, Pacak K, Neuzil J. Mitochondrial complex II: at the crossroads. *Trends Biochem Sci.* 2017;42(4):312–25. <https://doi.org/10.1016/j.tibs.2017.01.003>.
- Owens KM, Aykin-Burns N, Dayal D, Coleman MC, Domann FE, Spitz DR. Genomic instability induced by mutant succinate dehydrogenase subunit D (SDHD) is mediated by O<sub>2</sub>(-\*) and H<sub>2</sub>O<sub>2</sub>. *Free Radic Biol Med.* 2012;52(1):160–6. <https://doi.org/10.1016/j.freeradbiomed.2011.10.435>.
- Erb M, Hoffmann-Enger B, Deppe H, Soeberdt M, Haefeli RH, Rummey C, et al. Features of idebenone and related short-chain quinones that rescue ATP levels under conditions of impaired mitochondrial complex I. *PLoS One.* 2012;7(4):e36153. <https://doi.org/10.1371/journal.pone.0036153>.
- Haefeli RH, Erb M, Gemperli AC, Robay D, Courdier Fruh I, Anklin C, et al. NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels. *PLoS One.* 2011;6(3):e17963. <https://doi.org/10.1371/journal.pone.0017963>.
- Heitz FD, Erb M, Anklin C, Robay D, Pernet V, Gueven N. Idebenone protects against retinal damage and loss of vision in a mouse model of Leber's hereditary optic neuropathy. *PLoS One.* 2012;7(9):e45182. <https://doi.org/10.1371/journal.pone.0045182>.
- Turrens JF. Mitochondrial formation of reactive oxygen species. *J Physiol.* 2003;552(Pt 2):335–44. <https://doi.org/10.1113/jphysiol.2003.049478>.
- Cadenas E, Davies KJ. Mitochondrial free radical generation, oxidative stress, and aging. *Free Radic Biol Med.* 2000;29(3–4):222–30. [https://doi.org/10.1016/S0891-5849\(00\)00317-8](https://doi.org/10.1016/S0891-5849(00)00317-8).
- Palecek T, Fikrlé M, Nemecek E, Bauerova L, Kuchynka P, Louch WE, et al. Contemporary treatment of amyloid heart disease. *Curr Pharm Des.* 2015;21(4):491–506. <https://doi.org/10.2174/138161282104141204143657>.
- Strawser CJ, Schadt KA, Lynch DR. Therapeutic approaches for the treatment of Friedreich's ataxia. *Expert Rev Neurother.* 2014;14(8):949–57. <https://doi.org/10.1586/14737175.2014.939173>.

17. Lynch DR, Perlman SL, Meier T. A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia. *Arch Neurol*. 2010;67(8):941–7. <https://doi.org/10.1001/archneurol.2010.168>.
18. Buyse GM, Goemans N, van den Hauwe M, Thijs D, de Groot IJ, Schara U, et al. Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial. *Neuromuscul Disord*. 2011;21(6):396–405. <https://doi.org/10.1016/j.nmd.2011.02.016>.
19. Buyse GM, Voit T, Schara U, Straathof CS, D'Angelo MG, Bernert G, et al. Treatment effect of idebenone on inspiratory function in patients with Duchenne muscular dystrophy. *Pediatr Pulmonol*. 2017;52(4):508–15. <https://doi.org/10.1002/ppul.23547>.
20. McDonald CM, Meier T, Voit T, Schara U, Straathof CS, D'Angelo MG, et al. Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy. *Neuromuscul Disord*. 2016;26(8):473–80. <https://doi.org/10.1016/j.nmd.2016.05.008>.
21. Buyse GM, Voit T, Schara U, Straathof CSM, D'Angelo MG, Bernert G, et al. Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DEL05): a double-blind randomised placebo-controlled phase 3 trial. *Lancet*. 2015;385(9979):1748–57. [https://doi.org/10.1016/S0140-6736\(15\)60025-3](https://doi.org/10.1016/S0140-6736(15)60025-3).
22. Fiebiger SM, Bros H, Grobosch T, Janssen A, Chanvillard C, Paul F, et al. The antioxidant idebenone fails to prevent or attenuate chronic experimental autoimmune encephalomyelitis in the mouse. *J Neuroimmunol*. 2013;262(1–2):66–71. <https://doi.org/10.1016/j.jneuroim.2013.07.002>.
23. Seo Y, Park J, Kim M, Lee HK, Kim JH, Jeong JH, et al. Inhibition of ANO1/TMEM16A Chloride Channel by Idebenone and its cytotoxicity to Cancer cell lines. *PLoS One*. 2015;10(7):e0133656. <https://doi.org/10.1371/journal.pone.0133656>.
24. Augustyniak J, Lenart J, Zychowicz M, Stepień PP, Buzanska L. Mitochondrial biogenesis and neural differentiation of human iPSC is modulated by idebenone in a developmental stage-dependent manner. *Biogerontology*. 2017;18(4):665–77. <https://doi.org/10.1007/s10522-017-9718-4>.
25. Zhang J, Zhang J, Li T, Zhang N, Tang S, Tao Z, et al. Effect of idebenone on bone marrow mesenchymal stem cells in vitro. *Mol Med Rep*. 2018;17(4):5376–83. <https://doi.org/10.3892/mmr.2018.8506>.
26. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. *Nat Protoc*. 2013;8(11):2281–308. <https://doi.org/10.1038/nprot.2013.143>.
27. Ryall JG. Simultaneous measurement of mitochondrial and glycolytic activity in quiescent muscle stem cells. *Methods Mol Biol*. 2017;1556:245–53. [https://doi.org/10.1007/978-1-4939-6771-1\\_13](https://doi.org/10.1007/978-1-4939-6771-1_13).
28. Rafikov R, Sun X, Rafikova O, Louise Meadows M, Desai AA, Khalpey Z, et al. Complex I dysfunction underlies the glycolytic switch in pulmonary hypertensive smooth muscle cells. *Redox Biol*. 2015;6:278–86. <https://doi.org/10.1016/j.redox.2015.07.016>.
29. Hahn D, Kumar RA, Ryan TE, Ferreira LF. Mitochondrial respiration and H<sub>2</sub>O<sub>2</sub> emission in saponin-permeabilized murine diaphragm fibers: optimization of fiber separation and comparison to limb muscle. *Am J Physiol Cell Physiol*. 2019;317(4):C665–73. <https://doi.org/10.1152/ajpcell.00184.2019>.
30. Alleman RJ, Tsang AM, Ryan TE, Patteson DJ, McClung JM, Spangenburg EE, et al. Exercise-induced protection against reperfusion arrhythmia involves stabilization of mitochondrial energetics. *Am J Physiol Heart Circ Physiol*. 2016;310(10):H1360–70. <https://doi.org/10.1152/ajpheart.00858.2015>.
31. Goswami I, Perry JB, Allen ME, Brown DA, von Spakovsky MR, Verbridge SS. Influence of pulsed electric fields and mitochondria-cytoskeleton interactions on cell respiration. *Biophys J*. 2018;114(12):2951–64. <https://doi.org/10.1016/j.bpj.2018.04.047>.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

